S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20

Intec Pharma Insider Trades

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
988,300 shs
Average Volume
543,436 shs
Market Capitalization
$8.65 million
P/E Ratio
Dividend Yield

Intec Pharma (NASDAQ:NTEC) Insider Buying and Selling Activity

Insider Ownership

Number Of
Insiders Buying
(Last 12 Months)

Number Of
Insiders Selling
(Last 12 Months)

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get NTEC Insider Trade Alerts

Want to know when executives and insiders are buying or selling Intec Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Intec Pharma (NASDAQ NTEC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/3/2020Pharma Technologies Ltd DexcelMajor ShareholderSell80,000$0.32$25,600.004,424,897  
1/31/2020Pharma Technologies Ltd DexcelMajor ShareholderSell725,951$0.31$225,044.814,424,897  
11/19/2019Issac SilbermanDirectorSell1,000$0.49$490.00
8/28/2019Jeffrey A MecklerCEOBuy20,000$0.68$13,600.00196,761  
8/27/2019Anthony J MaddalunaDirectorBuy25,000$0.47$11,750.0053,570  
8/23/2019Jeffrey A MecklerCEOBuy100,000$0.46$46,000.00176,761  
(Data available from 1/1/2013 forward)

Intec Pharma (NASDAQ:NTEC) Insider Trade Frequently Asked Questions

Who is on Intec Pharma's Insider Roster?

The list of insiders at Intec Pharma includes Anthony J Maddaluna, Issac Silberman, Jeffrey A Meckler, and Pharma Technologies Ltd Dexcel.Learn more on NTEC's insiders

What percentage of Intec Pharma stock is owned by insiders?

3.30% of Intec Pharma stock is owned by insiders. Learn more on NTEC's insider holdings

Which Intec Pharma insiders have been selling company stock?

The following insider sold Intec Pharma stock in the last 24 months: Pharma Technologies Ltd Dexcel ($250,644.81).

How much insider selling is happening at Intec Pharma?

Insiders have sold a total of 805,951 Intec Pharma shares in the last 24 months for a total of $250,644.81 sold.

This page was last updated on 12/7/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.